Effects of the endothelin-converting enzyme inhibitor SM-19712 in a mouse model of dextran sodium sulfate-inducedcolitis

Inflammatory Bowel Diseases

Volumn 15, Issue 7, 2009, Pages 1007-1013

  Lee, Seungjun ^a   Carter, Patsy R ^a   Watts, Megan N ^a   Bao, Jianxiong R ^a   Harris, Norman R ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Colon; Endothelin converting enzyme; Inflammatory bowel disease; Vasoconstriction

Indexed keywords

4 CHLORO N [[(4 CYANO 3 METHYL 1 PHENYL 1H PYRAZOL 5 YL)AMINO]CARBONYL]BENZENESULFONAMIDE SODIUM; CD31 ANTIGEN; DEXTRAN SULFATE; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME INHIBITOR; MYELOPEROXIDASE; SM 19712; UNCLASSIFIED DRUG; ASPARTIC PROTEINASE; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN-CONVERTING ENZYME 1; ENZYME INHIBITOR; METALLOPROTEINASE; PEROXIDASE; SULFONAMIDE; SULFONYLUREA DERIVATIVE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD FLOW VELOCITY; COLITIS; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG MECHANISM; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; INTESTINE BLOOD FLOW; LOOSE FECES; MEAN ARTERIAL PRESSURE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OCCULT BLOOD; PRIORITY JOURNAL; VASCULAR RESISTANCE; VASOCONSTRICTION; WEIGHT REDUCTION; ANIMAL; BLOOD PRESSURE; BODY WEIGHT; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; COLON; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ILEUM; METABOLISM; ORGAN SIZE; VASCULARIZATION;

ANIMALS; ANTIGENS, CD31; ASPARTIC ENDOPEPTIDASES; BLOOD PRESSURE; BODY WEIGHT; COLITIS; COLON; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; ENZYME INHIBITORS; ILEUM; METALLOENDOPEPTIDASES; MICE; MICE, INBRED C57BL; ORGAN SIZE; PEROXIDASE; SULFONAMIDES; SULFONYLUREA COMPOUNDS; VASOCONSTRICTION;

EID: 69449087669     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20877     Document Type: Article

References (22)

1. Letizia C, Boirivant M, De Toma G, et al. Plasma levels of endothelin-1 in patients with Crohn's disease and ulcerative colitis. Ital J Gastroenterol Hepatol. 1998;30:266-269.
2. Kanazawa S, Tsunoda T, Onuma E, et al. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol. 2001;96:822-828.
3. Murch SH, Braegger CP, Sessa WC, et al. High endothelin-1 immunoreactivity in Crohn's disease and ulcerative colitis. Lancet. 1992;339: 381-385.
4. Hulten L, Lindhagen J, Lundgren O, et al. Regional intestinal blood flow in ulcerative colitis and Crohn's disease. Gastroenterology. 1977;72: 388-396.
5. Deniz M, Cetinel S, Kurtel H. Blood flow alterations in TNBS-induced colitis: role of endothelin receptors. Inflamm Res. 2004;53:329-336.
6. Gulluoglu BM, Kurtel H, Gulluoglu MG, et al. Role of endothelins in trinitrobenzene sulfonic acid-induced colitis in rats. Digestion. 1999;60:484-492.
7. Hogaboam CM, Muller MJ, Collins SM, et al. An orally active nonselective endothelin receptor antagonist, bosentan, markedly reduces injury in a rat model of colitis. Eur J Pharmacol. 1996;309:261-269.
8. Padol I, Huang JQ, Hogaboam CM, et al. Therapeutic effects of the endothelin receptor antagonist Ro 48-5695 in the TNBS/DNBS rat model of colitis. Eur J Gastroenterol Hepatol. 2000;12:257-265.
9. Anthoni C, Mennigen RB, Rijcken EJ, et al. Bosentan, an endothelin receptor antagonist, reduces leucocyte adhesion and inflammation in a murine model of inflammatory bowel disease. Int J Colorectal Dis. 2006;21:409-418.
10. Chidlow JH Jr, Langston W, Greer JJ, et al. Differential angiogenic regulation of experimental colitis. Am J Pathol. 2006;169:2014-2030.
11. Harris NR, Whatley JR, Carter PR, et al. Venular constriction of submucosal arterioles induced by dextran sodium sulfate. Inflamm Bowel Dis. 2005;11:806-813.
12. Mori M, Stokes KY, Vowinkel T, et al. Colonic blood flow responses in experimental colitis: time course and underlying mechanisms. Am J Physiol Gastrointest Liver Physiol. 2005;289:G1024-1029.
13. Vowinkel T, Kalogeris TJ, Mori M, et al. Impact of dextran sulfate sodium load on the severity of inflammation in experimental colitis. Dig Dis Sci. 2004;49:556-564.
14. Levin ER. Endothelins. N Engl J Med. 1995;333:356-363.
15. Matsumura Y, Kuro T, Kobayashi Y, et al. Protective effect of SM19712, a novel and potent endothelin converting enzyme inhibitor, on ischemic acute renal failure in rats. Jpn J Pharmacol. 2000;84:16-24.
16. Umekawa K, Hasegawa H, Tsutsumi Y, et al. Pharmacological characterization of a novel sulfonylureid-pyrazole derivative, SM-19712, a potent nonpeptidic inhibitor of endothelin converting enzyme. Jpn J Pharmacol. 2000;84:7-15.
17. Moolenbeek C, Ruitenberg EJ. The "Swiss roll": a simple technique for histological studies of the rodent intestine. Lab Anim. 1981;15:57-59.
18. Raab S, Thein E, Harris AG, et al. A new sample-processing unit for the fluorescent microsphere method. Am J Physiol. 1999;276:H1801-1806.
19. Dieleman LA, Palmen MJ, Akol H, et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol. 1998;114:385-391.
20. Cooper HS, Murthy SN, Shah RS, et al. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993; 69:238-249.
21. Vowinkel T, Mori M, Krieglstein CF, et al. Apolipoprotein A-IV inhibits experimental colitis. J Clin Invest. 2004;114:260-269.
22. McCartney SA, Ballinger AB, Vojnovic I, et al. Endothelin in human inflammatory bowel disease: comparison to rat trinitrobenzenesulphonic acid-induced colitis. Life Sci. 2002;71:1893-1904.